BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival

Role of Age and Sex in the Diagnosis of Early-stage Malignant Melanoma: A Cross-Sectional study

(2015) D Moreno-Ramírez et al.   ACTA DERMATO-VENEREOLOGICA

BRAF,NRASandMC1Rstatus in a prospective series of primary cutaneous melanoma

(2015) Z. García-Casado et al.   BRITISH JOURNAL OF DERMATOLOGY

The role ofBRAFmutations in primary melanoma growth rate and survival

(2015) V.J. Mar et al.   BRITISH JOURNAL OF DERMATOLOGY

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

(2015) Arnaud Uguen et al.   Diagnostic Pathology

Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma

(2015) Alexandra Thiel et al.   HUMAN PATHOLOGY

BRAF V600E mutation-specific antibody: A review

(2015) Lauren L. Ritterhouse et al.   SEMINARS IN DIAGNOSTIC PATHOLOGY

Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma

(2015) Nancy E. Thomas et al.   JAMA Oncology

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAFmutations

(2014) Michaela Angelika Ihle et al.   BMC CANCER

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

(2014) M S Carlino et al.   BRITISH JOURNAL OF CANCER

Association between BRAF V600E and NRAS Q61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma

(2014) Shaowei Wu et al.   CANCER CAUSES & CONTROL

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy

(2014) Andrew P. Barbour et al.   EUROPEAN JOURNAL OF CANCER

Prognostic value of BRAF mutations in localized cutaneous melanoma

(2014) Eduardo Nagore et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma

(2014) Darshil J. Shah et al.   MAYO CLINIC PROCEEDINGS

BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy

(2014) Diana Meckbach et al.   PLoS One

Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma

(2014) Diana Meckbach et al.   PLoS One

BRAF Mutations in Metastatic Malignant Melanoma

(2014) Laleh Ehsani et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAF V600E metastatic melanoma

(2013) J S Wilmott et al.   BRITISH JOURNAL OF CANCER

Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma

(2013) G. Safaee Ardekani et al.   BRITISH JOURNAL OF DERMATOLOGY

Emerging trends in the epidemiology of melanoma

(2013) V. Nikolaou et al.   BRITISH JOURNAL OF DERMATOLOGY

Clinical characteristics and outcomes with specificBRAFandNRASmutations in patients with metastatic melanoma

(2013) Amanda D. Bucheit et al.   CANCER

Usefulness of Immunocytochemistry for the Detection of the BRAFV600E Mutation in Circulating Tumor Cells from Metastatic Melanoma Patients

(2013) Véronique Hofman et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Tumor Necrosis Is a Prognostic Factor in Thick Cutaneous Melanoma

(2012) Rita Grude Ladstein et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma

(2012) Georgina V. Long et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

(2012) A. M. Menzies et al.   CLINICAL CANCER RESEARCH

BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma

(2012) Maria Colombino et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Importance of the Mitotic Marker Phosphohistone H3 in Cutaneous Nodular Melanoma

(2012) Rita G. Ladstein et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma

(2012) Graham J. Mann et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Detection of BRAF p.V600E Mutations in Melanomas

(2012) Emeline Colomba et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Evaluation of BRAF Mutation Testing Methodologies in Formalin-Fixed, Paraffin-Embedded Cutaneous Melanomas

(2012) Johanne Lade-Keller et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma

(2012) Molly Yancovitz et al.   PLoS One

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

(2011) David Capper et al.   ACTA NEUROPATHOLOGICA

Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort

(2011) Lu Si et al.   EUROPEAN JOURNAL OF CANCER

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

(2011) Bianca Devitt et al.   Pigment Cell & Melanoma Research

Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma

(2010) J. A. Ellerhorst et al.   CLINICAL CANCER RESEARCH